文献速递泌尿男性生殖肿瘤

仑伐替尼联合依维莫司对比卡博替尼治疗PD-1免疫检查点抑制剂进展后转移性透明细胞肾细胞癌的多中心随机II期试验(LenCabo)

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).
PubMed 文献 · Ann Oncol · 2025-10-18

这项多中心随机II期试验纳入90例既往接受过含PD-1免疫检查点抑制剂治疗的转移性透明细胞肾细胞癌患者,随机接受仑伐替尼联合依维莫司或卡博替尼治疗。结果显示仑伐替尼联合依维莫司较卡博替尼显著延长无进展生存期(中位15.7个月 vs 10.2个月,HR 0.51,95%CI 0.29-0.89,P=0.02),客观缓解率分别为52.6%和38.6%。总生存数据尚不成熟。

要点

  • PD-1免疫检查点抑制剂进展后,仑伐替尼联合依维莫司较卡博替尼显著延长无进展生存期。
  • 仑伐替尼联合依维莫司组因毒性停药率为20%,卡博替尼组为10.9%。
  • 总生存数据因事件数少尚不成熟,无法得出确切结论。

核心结论

  • 在既往PD-1免疫检查点抑制剂治疗进展后的转移性透明细胞肾细胞癌患者中,仑伐替尼联合依维莫司较卡博替尼显著延长无进展生存期。

研究设计与样本

  • 多中心、随机II期试验,采用贝叶斯最优II期设计,按IMDC风险组和既往靶向治疗分层。
  • 共随机90例既往接受过1-2线治疗(含PD-1免疫检查点抑制剂)的转移性透明细胞肾细胞癌患者;86例至少接受一剂指定治疗(仑伐替尼联合依维莫司组n=40,卡博替尼组n=46)。
  • 给药方案:仑伐替尼18 mg/天联合依维莫司5 mg/天,对比卡博替尼60 mg/天。

主要发现

  • 中位随访时间20个月(四分位距14.9-22.5个月),共观察到60例无进展生存事件。
  • 中位无进展生存期:仑伐替尼联合依维莫司组15.7个月,卡博替尼组10.2个月(HR 0.51,95%CI 0.29-0.89,P=0.02)。
  • 客观缓解率:仑伐替尼联合依维莫司组52.6%,卡博替尼组38.6%。
  • 总生存数据不成熟且无法得出结论(事件数24/86;1年总生存概率分别为87.0%和84.6%)。
  • 因毒性停药率:仑伐替尼联合依维莫司组20%,卡博替尼组10.9%。

临床怎么用

  • 对于PD-1免疫检查点抑制剂进展后的转移性透明细胞肾细胞癌,仑伐替尼联合依维莫司可作为二线或后线治疗选择,较卡博替尼显著改善无进展生存期。
  • 需注意仑伐替尼联合依维莫司组因毒性停药率较高(20% vs 10.9%),临床应用中应加强毒性管理。

局限性

  • 总生存数据不成熟,事件数少(24/86),无法就总生存差异得出结论。
  • 为II期试验,样本量有限(随机90例,可评估86例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line treatments for metastatic clear-cell renal-cell carcinoma (ccRCC) combine programmed cell death protein 1 (PD-1) immune checkpoint inhibition (ICI) with cytotoxic T-lymphocyte associated protein 4 ICI or angiogenesis targeted therapies (TT). Upon progression, common options include cabozantinib or lenvatinib + everolimus, although these regimens have never been directly compared. We hypothesized that lenvatinib + everolimus will improve progression-free survival (PFS) compared with cabozantinib after progression on PD-1 ICI. PATIENTS AND METHODS: This multicenter, randomized phase II trial enrolled patients with metastatic ccRCC previously treated with one to two lines including PD-1 ICI. Participants received lenvatinib 18 mg/day + everolimus 5 mg/day versus cabozantinib 60 mg/day, stratified by International Metastatic RCC Database Consortium risk group and prior TT. A Bayesian optimal phase II design was used. RESULTS: In total 90 patients were randomized; 86 patients received at least one dose of assigned lenvatinib + everolimus (n = 40) or cabozantinib (n = 46). Median time from randomization to data cut-off date (1 August 2025) was 20 months (interquartile range 14.9-22.5 months). A total of 60 PFS events were observed. Median PFS was 15.7 months with lenvatinib + everolimus and 10.2 months with cabozantinib [hazard ratio 0.51, 95% confidence interval (CI) 0.29-0.89, P = 0.02]. The objective response rate was 52.6% with lenvatinib + everolimus and 38.6% with cabozantinib. Overall survival (OS) data were immature and inconclusive due to a low number of events (n = 24/86; 1-year OS probability 87.0% versus 84.6% [95% CI 0.47% to 2.38%] with lenvatinib + everolimus versus cabozantinib, respectively. Discontinuation rates due to toxicity were 20% with lenvatinib + everolimus and 10.9% with cabozantinib. CONCLUSIONS: In this randomized phase II trial in metastatic ccRCC that progressed on prior PD-1 ICIs, lenvatinib + everolimus significantly prolonged PFS over cabozantinib. As the first head-to-head comparison of contemporary second-line or later treatments after ICI, these results are relevant to treatment sequencing and inform oncology practice.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hahn AW, Chahoud J, Skelton WP, et al. A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Ann Oncol. 2025. PMID: 41115467. doi:10.1016/j.annonc.2025.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。